Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Brokerages
Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has received a consensus rating of “Moderate Buy” from the five ...
Yahoo Finance5d
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting ...
Actinium Pharmaceuticals initiates Actimab-A Triplet combination frontline trial
Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development ...
Actinium Pharmaceuticals (NYSE:ATNM) Earns “Buy” Rating from HC Wainwright
Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga ...
Nasdaq5d
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...
H.C. Wainwright Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)
In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research ...
Investing6d
Actinium launches new AML treatment trial with NCI
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration ...
Kalkine Media4d
What Factors Are Driving Market Activity for Actinium Pharmaceuticals (NYSE:ATNM)?
Highlights,Actinium Pharmaceuticals operates in the biotechnology sector, focusing on targeted radiotherapies for oncology treatments.,Institutional participants have adjusted their holdings, ...
Investing6d
Actinium launches new AML treatment trial with NCI
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration with ...
Targeted Oncology4d
Actimab-A Triplet Trial Launches in Frontline AML
Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...
Pharmaceutical Technology on MSN4d
Telix’s new lead-212 generator could dispel medical isotope scalability hurdles
Telix states its automated and high-throughput generator can produce sufficient lead-212 elution for up to 60 clinical doses, ...
Cellectar Biosciences to Present at the 37th Annual Roth Conference
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today ...